Featured Research

from universities, journals, and other organizations

Anti-spasticity medications need further research

Date:
February 3, 2010
Source:
UT Southwestern Medical Center
Summary:
Only a few anti-spasticity medications used for children with cerebral palsy are backed by sufficient research to justify their use, according to a new review.

Only a few anti-spasticity medications used for children with cerebral palsy are backed by sufficient research to justify their use, according to a new review of scientific literature headed by a UT Southwestern Medical Center neurologist and conducted by a national panel of interdisciplinary experts nationwide.

The findings prompted the American Academy of Neurology to release a new practice guideline on effective treatments. Dr. Mauricio Delgado-Ayala, professor of neurology at UT Southwestern is lead author of the guideline, which appears in the Jan. 26 issue of the academy's journal, Neurology.

Botulinum toxin type A, sold under the brand names Botox and Dysport, is effective and generally safe to relieve spasticity, the researchers found. The drugs diazepam (Valium) and tizanidine (Zanaflex, Sirdalud) can also be used, although they carry more risks.

The researchers found insufficient evidence on whether other commonly used drugs are effective or safe.

A statement by the academy said that practice guidelines are intended to keep neurologists up to date on clinical research and improve medical treatment; they are not intended as hard-and-fast rules.

"The guideline identified a need for more research on most drugs used to treat generalized spasticity," said Dr. Delgado-Ayala. "These drugs might work and be safe, but that needs to be proved.

The lack of evidence does not mean that existing treatment methods are not effective and safe, but it should make us pause and realize that more research needs to be conducted."Most of the medications we use in children were originally studied in adults," Dr. Delgado-Ayala said. "We need to know more about how these medications work in the body, and the doses for best results and least side effects, not only to reduce spasticity but also to improve quality of life."

About 10,000 babies a year in the U.S. are born with cerebral palsy. Cerebral palsy comprises several types of movement disorders, sometimes accompanied by learning disorders, epilepsy and other conditions. The most common characteristic is spasticity, in which muscles tense and flex uncontrollably.

Botox and other drugs can be legally prescribed to treat spasticity, but this use is considered "off-label" because they have not been specifically approved by the Food and Drug Administration for that condition.

For the practice guideline panel, the American Academy of Neurology enlisted five pediatric neurologists, two developmental pediatricians, one pediatric physiatrist, one pediatric orthopedist and one adult neurologist. The panelists examined 218 research studies, all of which appeared in peer-reviewed journals and involved cerebral palsy patients under the age of 19, with at least nine patients studied. The panel made recommendations according to the level of evidence found.

Overall, the literature review identified a large "research gap," showing that the effectiveness, mechanism and safety of many drugs has not been adequately studied in children, Dr. Delgado-Ayala said.

"There is an urgent need to develop new drugs to treat spasticity in general," he said. "There has not been a new drug approved for spasticity by the FDA in more than 10 years."

Also participating were researchers from the National Institute of Neurological Disorders and Stroke; the Cerebral Palsy International Research Foundation; Loma Linda University; Bloorview Kids Rehab; the University of Washington, Seattle; the University of New Mexico; The Core Institute; Louisiana State University; and Cincinnati Children's Hospital.

The review was supported by the American Academy of Neurology.


Story Source:

The above story is based on materials provided by UT Southwestern Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

UT Southwestern Medical Center. "Anti-spasticity medications need further research." ScienceDaily. ScienceDaily, 3 February 2010. <www.sciencedaily.com/releases/2010/01/100127113746.htm>.
UT Southwestern Medical Center. (2010, February 3). Anti-spasticity medications need further research. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2010/01/100127113746.htm
UT Southwestern Medical Center. "Anti-spasticity medications need further research." ScienceDaily. www.sciencedaily.com/releases/2010/01/100127113746.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins